Tamtam Try Tamtam free
Pediatrix Medical Group logo

Pediatrix Medical Group account plan

Specialized care women children

At a glance

Pediatrix Medical Group is a US provider of newborn, maternal-fetal and pediatric physician services, with $1.91 billion net revenue in FY2025.

Pediatrix Medical Group (NYSE: MD), based in Sunrise, Florida, provides physician services in newborn, maternal-fetal and other pediatric subspecialty care, mainly in hospital NICUs. At December 31, 2025 it had approximately 2,295 affiliated physicians practising in 37 states, retained by approximately 400 hospitals, plus approximately 2,020 other clinical professionals and approximately 2,260 other employees. FY2025 net revenue was $1.91 billion (down 4.9% after exiting most office-based practices in 2024), with net income of $165.4 million and Adjusted EBITDA of $275.6 million. Texas alone produced about 32% of net revenue, and the five largest states about 64%.

Business units

Strategic priorities

Hospital-based and maternal-fetal focus
After exiting almost all office-based practices other than maternal-fetal medicine and its primary and urgent care line in 2024, management decided to return to a hospital-based and maternal-fetal medicine-focused organization; all practice dispositions are now behind it.
Nationwide telehybrid medicine
Pediatrix is building a teleservices function on top of its physical footprint of over 170 MFMs and over 360 NICUs, extending into retinopathy, neurology, infectious disease and neonatology, and has recruited a leader for it.
OB hospitalist expansion
The company is expanding OB hospitalist services across its relationships with over 400 hospitals and named select opportunities in the field as a growth priority in Q3 2026.
Acquisitions in women's and children's care
With leverage just under 1x and cash of $312 million, management says it can make larger acquisitions, staying in the women's and children's space, possibly with outside JV and capital investors.
Clinical data and technology
Its clinical data warehouse holds information on more than 2.1 million patients and is used to report outcomes to physicians and hospital partners, alongside charge-capture, cloud imaging and AI documentation tools.
Share buybacks
A $250.0 million programme was authorised in August 2025; $228.5 million had been used by September 30, 2026.

Latest results

In Q3 2026 net revenue rose 1.7% to $501.4 million, mainly from acquisitions net of dispositions, with same-unit revenue up 0.6%. Net income fell to $47.0 million from $71.7 million, as Q3 2025 included a $20.9 million gain on divested businesses, and Adjusted EBITDA was $85.5 million versus $87.3 million. Operating margin slipped to 13.0% from 13.8% as clinical salaries rose faster than revenue. Over nine months net revenue was $1.47 billion (+3.2%) and Adjusted EBITDA $220.1 million versus $209.7 million. The full-year 2026 Adjusted EBITDA outlook was narrowed to $290 million to $300 million; no 2027 outlook was given.

Investments and deals

Practice acquisitions
2025 acquisition payments were $23.2 million (one MFM practice plus a multi-practice neonatology, MFM and OB hospitalist deal); in 2026 one maternal-fetal medicine practice was acquired for total consideration of $7.9 million.
Stock repurchases
$147.2 million of stock was repurchased in the first nine months of 2026; about 10 million shares have been bought since August 2025 at an average $23.
Revenue cycle management transition
Pediatrix moved to a hybrid revenue cycle management model away from an outsourced provider; transformational and restructuring expenses were $22.3 million in 2025 and $19.5 million in the first nine months of 2026.

Challenges and risks

Medicaid and payor mix pressure
Government programs were 24% of FY2025 payor mix, and the One Big Beautiful Bill Act is expected by the CBO to cut federal Medicaid and CHIP spending; ACA premium increases of approximately 15% are proposed for 2027.
Declining volumes
Nine-month 2026 same-unit volume fell 0.9% with declines across all service lines, and a declining US birth rate is a stated risk; management expects 2026 volume flat to slightly down.
Rising clinical costs
Practice salaries and benefits rose 2.8% to $341.5 million in Q3 2026, with clinical salary growth of about 3% to 3.5%.
Debt maturity and state concentration
The credit agreement matures in February 2027, making the $178.1 million Term A Loan current, and about 64% of net revenue comes from five states.
Regulation and compliance
Surprise-billing rules and the IDR process, billing compliance, malpractice exposure, physician recruitment and retention, cybersecurity and AI use are named risks.

What leadership says

“we have a very strong balance sheet, and we have the ability to make larger acquisitions.”

Mark S. Ordan, Chief Executive Officer · Q3 2026 earnings call, October 29, 2026

“staying in the women's and children's space is important to us.”

Mark S. Ordan, Chief Executive Officer · Q3 2026 earnings call, October 29, 2026

“telemedicine without a physical link is an imperfect offering”

Mark S. Ordan, Chief Executive Officer · Q2 2026 earnings call, August 4, 2026

“our adjusted EBITDA will be fairly ratable in the third and fourth quarters.”

Kasandra H. Rossi, Chief Financial Officer · Q2 2026 earnings call, August 4, 2026

Where a supplier can help

Telehealth platform and devices
The nationwide telehybrid build-out across MFM, neonatology, retinopathy, neurology and infectious disease needs virtual-care software, remote imaging and connectivity suppliers.
Revenue cycle automation
With the hybrid revenue cycle model now steady and further automation being explored, billing, coding and collections technology can protect pricing as the collections tailwind fades.
Physician recruiting and retention
Clinical salary growth and physician recruitment and retention risk make staffing, credentialing and workforce-scheduling tools relevant to the OB hospitalist and telehybrid expansion.
M&A integration support
The stated appetite for larger women's and children's acquisitions creates demand for diligence, practice integration and IT migration services.
Security and AI governance
Cybersecurity, privacy and AI use are named risks while AI documentation tools roll out, a fit for compliance and security vendors.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Pediatrix Medical Group?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Pediatrix Medical Group

What does Pediatrix Medical Group do?

Pediatrix provides physician services in newborn, maternal-fetal and other pediatric subspecialty care. Its affiliated physicians staff and manage over 360 NICUs in 32 states and are retained by approximately 400 hospitals.

What is Pediatrix's revenue?

FY2025 net revenue was $1.91 billion, with net income of $165.4 million and Adjusted EBITDA of $275.6 million. Nine-month 2026 net revenue was $1.47 billion.

How many physicians work with Pediatrix?

At December 31, 2025 the network had approximately 2,295 affiliated physicians in 37 states, plus approximately 2,020 other clinical professionals.

What is Pediatrix's strategy?

It is refocused on hospital-based and maternal-fetal medicine care, building nationwide telehybrid services, expanding OB hospitalist services, and looking for acquisitions in women's and children's health.

Who leads Pediatrix Medical Group?

Mark S. Ordan is Chief Executive Officer and Kasandra H. Rossi is Chief Financial Officer.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)